NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Well Doc, since the Proneural group's survival is not promoted by the utilization of DCVax-L, I am not mourning the removal of this group from the trial because those patients would have diluted the survival advantage of the Treatment group vis a vis the Controls. However, I am guessing that many patients with the Proneural GBM demonstrated early pseudo-progression and had already been removed from the trial before randomization. So now we are rid of the remaining members of this group.

However, I am confident that we can rely especially on mesenchymal antigenic pattern to give us a homerun.

I don't know of treatments that are more successful in treating the most aggressive form of a primary cancer while being a much less successful treatment for a relatively milder antigenic form of the disease. in this respect, DCVax-L seems to be an exception.